Experimental data demonstrate a mode of action (MOA) for liver tumors in male rats and mice treated with sedaxane that starts with activation of CAR, followed by altered expression of CAR-responsive genes, increased cell proliferation, and eventually clonal expansion of preneoplastic cells, leading to the development of altered foci and tumors. This MOA is nonrelevant to human risk assessments. Methods and results in the MOA work for sedaxane illustrate promising directions that future MOA studies may be able to employ, in the spirit of "Tox21" and reduction of in vivo animal use: (1) currently available in vitro CAR and PXR reporter assays demonstrated that sedaxane is a direct CAR activator in mice and rats, and a weak PXR activator in rats; (2) mouse liver microarray results compared with a published CAR biomarker signature (based on 83 genes) showed a clear, statistical match, and a lack of correlation to similar biomarker signatures for AhR, PPARa, and STAT5B; (3) Ki67 immunohistochemistry and zonal image analysis showed significant increases in this marker of cell proliferation in mouse liver, without the need to dose a DNA labeling agent; and (4) toxicokinetic analysis of Cmax levels of sedaxane in blood showed a marked species difference between mice and rats that helps to explain differences in sensitivity to sedaxane. Incorporating these tools into the study plan for a new agrochemical or drug during development offers a promising alternative to the traditional need to conduct later, specialized MOA studies after the results of chronic bioassays are known.
Sedaxane is a fungicide of the succinate dehydrogenase inhibitor (SDHI) class that is registered for use globally as a seed treatment. The US EPA and Canadian PMRA have concluded that, following chronic dietary administration, treatment with a high dose of sedaxane resulted in a higher incidence of liver tumors in male Wistar rats (at 3600 ppm) and male CD-1 mice (at 7000 ppm) (PMRA, 2012; U.S. Environmental Protection Agency, 2011c) . In the past 15 years, published research has established a range of different modes of action (MOAs) that can lead to rodent liver tumors (Cohen, 2010) , and a framework has been described by the International Programme on Chemical Safety (IPCS) and the International Life Science Institute (ILSI) to evaluate the weight of evidence supporting a particular MOA in rodents (Boobis et al., 2006; Meek et al., 2003 Meek et al., , 2014 . If an MOA is established in animals, the IPCS/ILSI framework also provides a logical set of criteria to evaluate whether that MOA is relevant to humans. In the current manuscript, experimental data supporting a MOA for rodent liver tumors with sedaxane via activation of the constitutive androstane receptor (CAR) and/or the pregnane X receptor (PXR) and this MOA's non-relevance to humans is described, within the IPCS/ILSI framework.
In addition to recent advances in the understanding of rodent liver tumor MOAs and the level of experimental proof needed to establish them, key changes in the direction of toxicology research in recent years have been signaled by "Toxicity Testing in the 21st Century" (National Research Council, 2007) and related programs of work, such as Tox21 and RISK21 (Kavlock et al., 2012; Pastoor et al., 2014) . This vision and its enactment have emphasized a need to move away from large-scale, high-dose testing of new agrochemicals and drugs in vivo in animals, and instead to develop reliable tools that utilize in vitro methods (particularly human); evaluation of exposure and toxicokinetics; and more limited in vivo testing at human-relevant dose levels. In the spirit of this vision, the current MOA manuscript for sedaxane will illustrate both traditional MOA experiments to demonstrate key events in the CAR/ PXR MOA and use of in vitro tools, plus extensive use of toxicogenomics and existing tissue data (in a manner that could be applied to samples from required short-term toxicity studies in rodents), to help build wider experience and trust in the ability of these tools to replace the more animal-intensive, traditional MOA studies. In particular, this paper will demonstrate:
• Use of CAR3 reporter assays (Omiecinski et al., 2011) and PXR reporter assays to investigate the relative ability of sedaxane to activate CAR from mouse, rat, and human subjects;
• Use of data from whole mouse liver microarrays and comparisons of the differentially expressed genes (DEGs) to published mRNA signatures for activators of nuclear receptors (CAR, AhR, PPARa, and STAT5b) (Oshida et al., 2015a (Oshida et al., , b, c, 2016 );
• Use of Ki67 immunohistochemistry as a marker of cell proliferation in the liver, as an alternative to exogenously administered DNA synthesis labels (eg, BrdU, EdU, and 3 H-thymidine). Ki67 is an endogenous marker that is increased in all phases of the cell cycle except G0 (the resting phase), and as such is applicable for use in analysis of existing tissues of prior repeat-dose studies in rodents. The presence of Ki67 in livers from a prior MOA study with sedaxane was visualized and quantified within different zones of liver hepatocytes, as a further enhancement to maximize the ability to detect any treatment-related differences; and • Use of toxicokinetics data from blood or plasma at steady state to understand differences in responsiveness to sedaxane in male mice and male rats.
The data presented in this manuscript establish that the sedaxane MOA in rats and mice is via activation of CAR (and, to a small extent, via PXR activation in rats), as illustrated by the set of key events and associative events depicted in Figure 1 . Although CAR activation was shown to be the major driver for subsequent effects in the liver with sedaxane, in the interest of simplicity, the remainder of the manuscript will refer to the initial key event as "CAR/PXR activation." With sedaxane, the critical key event of increased cell proliferation was shown to occur in both mice and in rats at tumorigenic dose levels in vivo, and in primary rat hepatocytes in vitro, but it did not occur in primary human hepatocytes. Therefore, based on the data presented and prior reviews that have summarized the wider literature on CAR/PXR activation (Elcombe et al., 2014; Whysner et al., 1996; Yamada et al., 2009 Yamada et al., , 2014 , the MOA via CAR/PXR activation is considered to be not relevant to humans, based on qualitative differences in their response to CAR/PXR activation compared with the responses observed in mice and rats. Animals and treatment. An illustration of the study designs for in vivo MOA studies in male rats and male mice is provided in Figure 2 . For rats, MOA studies and prior repeat-dose toxicity studies were primarily conducted on male Wistar rats [strain: Crl: WI(Han)] of approximately 8 weeks of age, as supplied by Charles River (UK) Limited, Margate, Kent, UK. The MOA study was conducted at Sequani Limited, Ledbury, Herefordshire, UK and other supporting laboratories. Animals were treated with either control, sedaxane, or NaPB diets and sacrificed after 1, 3, 7, 14, or 28 days of treatment. In addition, a recovery group was treated for 28 days, followed by a 60-day recovery period.
MATERIALS AND METHODS

Chemicals
For mice, MOA studies and prior repeat-dose toxicity studies were conducted on male CD-1 mice [strain: Crl: CD-1 (ICR)], approximately 6-8 weeks of age, supplied by Charles River (UK) Limited, Margate, Kent. The MOA study in male mice was conducted at Charles River Laboratories (CRL), Tranent, Edinburgh, UK and other supporting laboratories. Animals were treated with control or sedaxane diets and sacrificed after 1, 3, 7, or 21 days treatment. A positive control group was dosed twice with 3 mg/kg TCPOBOP (or DMSO vehicle) by ip injection, which was similar to the method reported by Tojima and colleagues (Tojima et al., 2012) .
Dietary test material preparation and analysis. Sedaxane was administered at fixed concentrations (ppm) in the diet [Rat and Mouse (Modified) No. 1 SQC Expanded Ground Diet, Special Diet Services, Witham, Essex, UK]. Homogeneity and concentration were assessed by validated analytical methods. Test material intakes (mg test material/kg body weight/day) were calculated at the end of the study using the theoretical test material concentrations in the feed, body weights, and measured food consumption. In MOA studies, male rats were treated with diet containing sedaxane at concentrations up to the carcinogenic level (3600 ppm) from the 2-year rat study, and at a lower noncarcinogenic level (1200 ppm). Male mice were treated at the carcinogenic level (7000 ppm) and a non-carcinogenic level (1250 ppm) from the 18-month mouse study, and a higher dose level (14 000 ppm) was also included to maximize the response in short-term studies in light of the known lower responsiveness of mice compared with rats for the systemic effects of sedaxane. In addition, existing tissues from prior short-term dietary studies were used for mechanistic work, with dietary concentration levels that ranged up to 5000 ppm for rats and up to 7000 ppm for mice.
BrdU administration. In MOA studies, 5-bromo-2 0 -deoxyuridine (BrdU) was administered to each rat or mouse at a dose level of 75 mg/kg body weight by subcutaneous injection, approximately 2 h prior to termination.
Termination and sampling. On each of the designated necropsy days, animals were killed by exposure to carbon dioxide gas in a rising concentration. Blood samples were taken from all animals, either from the orbital sinus under isoflurane anaesthesia (mice) or from the vena cava before exsanguination at necropsy (rats), and were then processed to provide terminal plasma samples. Terminal plasma samples were analyzed for selected clinical chemistry endpoints. The livers from all animals were collected, weighed, and processed as described below.
• Histopathology samples. For rats: representative sections from the left lateral lobe, the right median lobe, and the caudate lobe of the liver were taken. For mice: representative sections from the left and median lobes (through the bifurcation) were taken, including from the gall bladder. A section of the duodenum was also preserved to serve as a positive control for BrdU incorporation. These samples were taken into 10% neutral buffered formalin and processed after 48 h of fixation to paraffin wax blocks.
Tissues did not sit in hot wax for >2 h.
• Toxicogenomic samples. Two tissue sections of the liver were taken from the left lateral lobe and immersed in RNAlater TM Stabilization Solution reagent in an RNAase free tube, and then stored in a refrigerator overnight (nominal temperature 4 C) before storage in a freezer (À80 C).
• Liver Biochemistry samples. For rats: an approximately 2 g sample of liver was taken from the left lateral lobe, snap frozen in liquid nitrogen, and stored in a freezer (À80 C). For mice: the remaining liver was cut into cubes and stored at À80 C.
Histopathology of the liver. From paraffin-embedded liver samples, 5 mm sections were processed to obtain hematoxylin-and eosin-stained (H&E) slides, and then these were examined by a veterinary pathologist.
Analysis of sedaxane in blood. In a subchronic toxicity study in male Wistar rats, sedaxane (with a 50:50 ratio of trans-and cisisomers) was administered in the diet at 0, 500, 2000, and 5000 ppm for 28 days. At regular intervals beginning 8 h after administration of test diets on Day 1 or Day 14, serial blood samples (0.1-0.2 ml) were taken at 17:00, 21:00, 01:00, 05:00, 09:00, and 13:00 h. Blood samples were centrifuged, and plasma was stored frozen at approximately À20 C until analysis. In a Figure 2 . Designs of the investigative rat and mouse studies illustrating the various treatment groups, sample collection time-points (days), and assessments. In the mouse study, a positive control substance (TCPOBOP; Tojima et al., 2012) preliminary 14-day mouse study, sedaxane (with an 83.0:12.3 ratio of isomers) was administered to male CD-1 mice at 0, 7000, 10 000, and 14 000 ppm in the diet. Blood samples were taken by cardiac puncture under CO 2 anesthesia into EDTA tubes at the time of sacrifice (in the morning). Whole blood samples were diluted with an equal volume of water and frozen prior to analysis. Rat plasma and mouse blood samples were analyzed by HPLC for determination of the trans isomer (SYN508210) and the cis isomer (SYN508211) of sedaxane.
BrdU labeling index. Liver sections (5 mm) were processed to slides and stained for immunohistochemistry detection of BrdU with 3,3 0 -diaminobenzidine (DAB, for rats) or fluorescent tyramide (FITC, for mice) by standard methods (Deng et al., 2009; Eldridge et al., 1990) . Slides were counterstained with hematoxylin (for rats) or TOPRO-3 (for mice) to visualize the cell nuclei. The BrdU labeling index (number of BrdU-stained nuclei/total hepatocyte nuclei Â 100%) was determined by counting approximately 1000 nuclei (per rat) or 2000 nuclei (per mouse) (Deng et al., 2009; Eldridge et al., 1990) .
Ki67 labeling index. For mouse livers, an additional two 5 mm sections of the histopathology samples in wax blocks were cut, mounted on glass slides, and stained for immunohistochemistry detection of Ki67 by standard methods (Bahnemann and Mellert, 1997; Muskhelishvili et al., 2003) . A DAB chromagen was used to identify Ki67 containing nuclei, and the slides were counterstained with hematoxylin to visualize tissue morphology and all of the cell nuclei. Using semi-automated image analysis, the Ki67 labeling index was evaluated quantitatively within each of 3 liver zones (Zone 1 ¼ periportal, Zone 2 ¼ midzonal, and Zone 3 ¼ centrilobular) (Bahnemann and Mellert, 1997, see Supplementary Figure S1) , plus values for all 3 zones combined. A computerized random number generator was used to select 9 grid squares (approximately 2 mm Â 2 mm each) that contained a portal triad, midzonal region, and central vein (ie, representing liver Zones 1, 2, and 3, respectively). For each region of interest (ROI), 3 parameters were evaluated: (1) the total number of hepatocyte nuclei; (2) the number of Ki67-immunostained hepatocyte nuclei; and (3) the ROI total area. Detection of immunostained and non-immunostained hepatocyte nuclei within each ROI occurred automatically via user-defined colorimetric, size, and shape thresholds. The Ki67 labeling index (number of Ki67-stained nuclei/total hepatocyte nuclei Â 100%) was determined in accordance with Bahnemann and Mellert (1997) , both for Zones 1, 2, and 3, and then for all zones combined.
Hepatic gene expression data. The expression of selected genes in mouse liver was measured by real-time polymerase chain reaction (RT-PCR), based on CAR-mediated gene expression that was observed with the model mouse CAR activator TCPOBOP (Tojima et al., 2012) . Total RNA was extracted from all the liver samples stored in RNAlater TM Stabilization Solution using
Qiagen RNeasy V R Mini Kits, and reverse transcription of each total RNA preparation was performed as described previously (Meredith et al., 2003) . The cDNA preparation from each animal was assayed for Cyp2b10, Cyp2c65, Gadd45b, Cdc20, and Fos mRNA levels based on assay kits from Life Technologies (Supplementary Table S1 ). To normalize for RNA loading, mouse liver mRNA levels were expressed as ratios to levels of b-actin mRNA. Each mouse cDNA preparation was assayed in duplicate for each of the mRNAs listed above by RT-PCR methodology (TaqMan V R ) employing an Applied Biosystems ABI PRISM 7700 sequence detector (Meredith et al., 2003) . Statistical comparisons between control and treated groups were performed on the DCt values, where Ct is the threshold cycle. Fold-change of each gene relative to the untreated control samples was calculated as 2 to the power of the -DDCt value. Mouse microarrays were utilized to evaluate gene expression changes across the whole mouse genome. Liver biochemistry samples, stored frozen, were used from Days 2, 4, and 22 of treatment. The RNA was extracted from frozen mouse liver samples into Tri Reagent (Sigma, T9424-100 ml), purified using RNeasy mini-columns (Qiagen GmbH #75144), and checked for integrity (Agilent 2100 Bioanalyzer Instrument and Agilent RNA 6000 Nano Kit). Total RNA (50 ng) was labeled with Cyanine 3-CTP (Cy3), a fluorescent dye which enables visualization and quantification when scanned, prior to microarray hybridization using the Agilent Low Input Quick Amp Labeling Kit, 1 color (Agilent #5190-2305 (Oshida et al., 2015a) .
Biochemical analysis and enzyme activities. The liver biochemistry samples were taken from the left lateral lobes (rats) or the remaining livers (mice) and stored frozen prior to analysis. Whole homogenates, microsomal fractions, and cytosolic fractions were prepared as described previously, and their protein contents were determined (Lake, 1987) . Liver whole homogenates were assayed for cyanide-insensitive palmitoyl-CoA oxidation activity as described previously (Gray et al., 1983) , but with the addition of 10 mM FAD to each cuvette. Hepatic microsomal Cytochrome P450 (CYP) content, 7-pentoxyresorufin Odepentylase (PROD) activity, and 7-ethoxyresorufin O-deethylase (EROD) activity were determined spectrophotometrically, as described previously (Japenga et al., 1993; Lake, 1987) . Hepatic microsomal testosterone 6b-hydroxylase activity, testosterone 16b-hydroxylase activity, and lauric acid 12-hydroxylase activity were determined as described previously (Lake et al., 1996; Lake et al., 1998) by ultra-performance liquid chromatography-mass spectrometry-mass spectrometry (UPLC-MS-MS).
Primary hepatocytes cultures. Rat hepatocytes were isolated by insitu perfusion from male Han Wistar rats according to Mitchell et al. (1984) , and cryopreserved human hepatocytes were obtained from Life Technologies (Cheshire, UK), and then these were cultured under standard conditions (Bars et al., 1989; Mitchell et al., 1984) . Hepatocytes were exposed to increasing concentrations of sedaxane or sodium phenobarbital, and to epidermal growth factor (EGF, 25 ng/mL) as a positive control for replicative DNA synthesis. After 96 h in culture, hepatocytes were fixed in methanol and the DNA labeling index was determined immunocytochemically, following the incorporation of BrdU into hepatocyte nuclei (700-1600 hepatocytes counted per replicate) over the last 3 days of culture (Bars et al., 1989; Mitchell et al., 1984) . Cytotoxicity was assessed using the CellTiter-Glo V R Luminescent Cell Viability Assay (Promega, UK). Benzyloxyresorufin-O-debenzylation (BROD) activity in cultured hepatocytes was determined as described by Burke et al. (1985) .
Reporter assays for CAR and PXR activation. Sedaxane was tested for its ability to directly activate the constitutive androstane receptor (CAR) in a reporter assay that was developed at Penn State University (Omiecinski et al., 2011) . Briefly, cDNA expression vectors for CAR3 variants of mouse, rat, and human CAR were transfected into COS-1 cells (purchased from ATCC, Manassas, VA), along with necessary cofactors and a CYP2B6 response element-luciferase reporter construct. After a suitable expression time, the cells were incubated with sedaxane at concentrations of 1, 3, 10, and 30 mM. Model direct-acting substrates for mouse, rat, or human CAR (TCPOBOP, clotrimazole, and CITCO, respectively) were each incubated at a single concentration. Light emission from the luciferase reporter was quantified to indicate the extent of CAR activation upon incubation with suspected ligands, including sedaxane. Results were reported as normalized luciferase activity and fold-change compared with a DMSO solvent control. Cell viability was also assessed using a CellTiter-Glo V R Luminescent Cell Viability Assay (Promega). Sedaxane was tested in commercially available PXR transactivation assays (INDIGO Biosciences, Inc., State College, PA) for its ability to activate PXR in reporter assays for mouse, rat, and human PXR (see Vanden Heuvel, 2009; nrresource.org) . In human embryonic kidney (HEK) cells, the ligand-binding domain of human, rat, or mouse PXR was fused to the DNA binding domain of the transcription factor Gal4, in the presence of a Gal4-luciferase reporter. Concentrations of sedaxane from 0.014 to 30 mM were tested in the PXR reporter assay system along with T0901317 and pregnenolone-16a-carbonitrile as positive or negative control compounds (Mitro et al., 2007; Ostberg et al., 2002) . After 24 h, the emission of light was measured to quantify the relative light units (RLUs), which are surrogate measures of PXR activity. Cell viability was also assessed using INDIGO's Live Cell Multiplex (LCM) assay.
Statistical analysis. Results were expressed as the mean 6 SD. For in vivo studies and primary hepatocyte experiments, control and sedaxane-treated groups were subjected to a 1-way analysis of variance (ANOVA), and comparisons between control and sedaxane treated groups were made using two-sided Dunnett's tests or Student's t-tests. Separate comparisons between the negative control group and the positive control treated groups (NaPB or TCPOBOP) were made using ANOVA and two-sided Dunnett's tests or Student's t-tests. To compare relative liver weights after adjustment for body weight, liver weights were considered by analysis of covariance (ANCOVA) on final body weights, followed by Dunnett's tests. In pairwise test comparisons for in vivo data, a probability level of p < .05 was taken to indicate statistical significance. Hepatic Cyp2b10, Cyp2c65, Gadd45b, Cdc20, and Fos mRNA levels by RT-PCR were examined for outliers, and statistical comparisons were performed on expression levels of control versus treated groups (expressed as DCt values), prior to calculation of the fold-change versus controls. Possible outlier values are discussed in the Results, and statistics were performed with and without these influential values. The Ki67 labeling index from mice studies (for liver zones 1, 2, and 3 and for all zones combined) was compared by 1-way ANOVA followed by Student's t-test, with statistical significance set at p < .05.
For in vitro reporter assays for CAR or PXR transactivation, control and sedaxane-treated groups were examined by 1-way ANOVA followed by Dunnett's test, whereas control and positive control groups (at a single concentration) were examined by a two-tailed unpaired t-test. Significance was declared if p < .01 in the reporter assays, based on the levels of variability typically seen in these experiments.
Other statistical methods for certain data types are described in the captions to the appropriate tables or figures.
RESULTS
The proposed MOA for sedaxane-induced livers tumors in rats and mice ( Figure 1 ) matches that of known CAR/PXR activating compounds (Elcombe et al., 2014; Huang et al., 2005; Yamada et al., 2009) . The key events for sedaxane-mediated rodent livers tumors include the following: (1) CAR/PXR activation; (2) altered expression of CAR-responsive genes; (3) transiently increased hepatocellular proliferation; and (4) clonal expansion and development of altered foci, with an eventual increase in hepatocellular tumors. Associative events that co-occur with these key events can serve as useful markers of the key events, and these include: (1) increased expression of Cyp2b and Cyp3a genes; (2) increased enzyme activity corresponding to increased CYP2B and CYP3A proteins; (3) hepatocellular hypertrophy; (4) decreased apoptosis in the liver; and (5) increased liver weights. The data that support these key events and associative events are described in the following sections.
Tumor Response in Male Rats and Male Mice
Male Wistar rats, provided sedaxane in the diet at 0, 200, 1200, and 3600 ppm for up to 104 weeks in a regulatory guideline study, exhibited a slightly higher incidence of hepatocellular adenomas at 3600 ppm. The incidences of hepatocellular adenomas, as well as selected non-neoplastic findings in the liver after 104 weeks, are shown in Supplementary Table S2 . The US EPA (U.S. Environmental Protection Agency, 2011c) performed its standard set of statistical tests on these data, including:
(1) excluding of all animals that died before the first tumor occurred; (2) performing a one-side Fisher's Exact Test on the control versus treated group tumor rates; and (3) performing a one-sided Exact Trend Test on the data, which takes age as well as incidence into account. The incidence of hepatocellular adenomas at 3600 ppm (10%) was not statistically different from the control group incidence (2%), but the Exact Trend Test showed a statistically significant trend (p ¼ .01656). The EPA concluded that the incidence in 3600 ppm males was weak evidence of a treatment-related effect.
Male CD-1 mice, provided sedaxane in the diet at 0, 200, 1250, and 7000 ppm for up to 80 weeks in a regulatory guideline study, exhibited a higher incidence of hepatocellular adenomas and carcinomas at 7000 ppm. The incidences of hepatocellular adenomas and carcinomas, as well as selected non-neoplastic findings in the liver, are shown in Supplementary Table S3. As described for the rat 104-week data, the US EPA (2011c) performed its standard set of statistical tests on these data in mice, including statistics on the combined incidence of adenomas plus carcinomas. The incidences of adenomas and of combined hepatocellular tumors were statistically significantly higher at 7000 ppm than the corresponding control incidences, as shown by the pairwise Fisher's Exact Test, and the Exact Trend Test found statistically significant differences in incidences of adenomas, carcinomas, and combined hepatocellular tumors. The EPA concluded that liver tumors in male mice were treatmentrelated only at the 7000 ppm dose.
Nonneoplastic Changes in Carcinogenicity Studies
In male rats at 104 weeks (Supplementary Table S2 ), the incidence of centrilobular hypertrophy was statistically significantly higher than the control group for 1200 and 3600 ppm males. In contrast, the incidence of eosinophilic foci (a common pre-neoplastic finding in a CAR-mediated tumor MOA; Goldsworthy and Fransson-Steen, 2002; Tamura et al., 2015) was significantly higher only at the tumorigenic dose level of 3600 ppm. There were no other histopathology findings in the livers of male rats at 104 weeks that were considered to be related to treatment. At the 52-week interim sacrifice (Supplementary Table S4 ), the 3600 ppm male rats showed significantly lower body weight gain (À19%), and statistically significantly higher relative liver weights (þ41%), plus centrilobular hypertrophy (11/12 rats) and hepatocyte pigmentation (7/12 rats), as compared with the controls (0/12 incidence). The 1200 ppm males showed only a small increase in relative liver weight (þ18%, p < .05), and the 200 ppm males showed no differences from controls for any of these endpoints.
In male mice at 80 weeks (Supplementary Table S3) , there were no effects of treatment on the incidences of nonneoplastic liver changes, including eosinophilic foci and centrilobular hypertrophy.
Liver Weights and Hepatic Histopathology in Short-Term Studies
In a 28-day toxicity study, male rats treated with sedaxane in the diet at 0, 500, 2000, and 5000 ppm showed statistically significant increases in mean liver weights at 2000 and 5000 ppm (34% and 76% higher than control, respectively); these increases in mean liver weights were associated with statistically significant higher incidences of centrilobular hypertrophy observed histologically at 2000 and 5000 ppm (Supplementary Table S5 ). These findings are consistent with the increased mean liver weight (36% higher than control) and increased incidence of centrilobular hypertrophy noted in a guideline toxicity study in which rats were provided with 4000 ppm sedaxane in the diet for 90 days (Supplementary Table S6 ).
In the 21 day MOA study (Figure 2 ), male mice treated with sedaxane in the diet at 0, 1250, 7000, and 14 000 ppm showed statistically significant increases in mean liver weights at 7000 ppm on Days 8 and 22 (15% and 12% higher than control, respectively) and at 14 000 ppm on Days 4, 8, and 22 (20%, 29%, and 33% higher than control, respectively) (Supplementary Table S7 ). These increases in mean liver weights were associated with statistically significant higher incidences of centrilobular hypertrophy observed histologically at Day 22 at 7000 and 14 000 ppm (Supplementary Table S8 ).
Activation of CAR and/or PXR Sedaxane was evaluated in an in vitro CAR3 reporter assay for its ability to activate CAR from rat, mouse, and human by a method that has previously been shown to detect known species-specific activators of this nuclear receptor (Omiecinski et al., 2011) . In addition, sedaxane was evaluated using commercially available PXR reporter assays for rat, mouse, and human PXR. In each assay, model compounds that are known to activate the specific CAR or PXR receptors were also tested to confirm the performance of the assays. Results for sedaxane in CAR and PXR reporter assays (rat, mouse, and human) are shown in Figure 3 .
Sedaxane produced statistically significant increases in rat CAR activation at 10 and 30 lM (p < .01), with a maximum increase of 6.3-fold versus control at 30 lM. Sedaxane also was classified as a possible rat PXR activator, with a statistically significant maximal increase of 3.1-fold versus control at the highest test concentration of 30 lM, but much lower changes at 1.1-10 lM (1.3-1.7-fold). The model activators clotrimazole (for rat CAR, 95-fold increase) and pregnenolone-16a-carbonitrile (for rat PXR, 79-fold increase) produced large fold-changes in activation of the respective reporter constructs, demonstrating that the assays responded as expected.
Sedaxane produced statistically significant increases in mouse CAR activation at 3, 10, and 30 lM (p < .01), with a maximum increase of 19-fold versus controls at 30 lM. In contrast, sedaxane did not activate mouse PXR. The model activators TCPOBOP (for mouse CAR, 45-fold increase) and pregnenolone16a-carbonitrile (for mouse PXR, 3-fold increase) produced large fold-changes in activation of the respective reporter constructs, demonstrating that the assays responded as expected.
Sedaxane produced a statistically significant increase in human CAR activation at 30 lM (p < .01), with a maximum increase of 4-fold versus controls. Sedaxane also was an activator of human PXR, with a statistically significant maximal increase of 3.9-fold versus controls at the highest test concentration of 30 lM, and smaller increases at 3.3 and 10 lM (1.7 and 3.0-fold). The model activators CITCO (for human CAR, a 10-fold increase) and TO901317 (for human PXR, a 27-fold increase) produced large fold-changes in activation of the respective reporter constructs, demonstrating that the assays responded as expected.
Liver Enzyme Activities in Mice and Rats
Liver fractions were taken and stored at À70 C at the conclusion of subchronic toxicity studies for male CD-1 mice or male Wistar rats after 4-13 weeks of treatment, and results of their subsequent analysis are included in Supplementary Figure S2  for mice and Supplementary Table S5 for rats. In male mice treated at the tumorigenic dose level of 7000 ppm for 4 weeks or 13 weeks, PROD activity was significantly increased by 19-fold and 14-fold, respectively. The PROD activity following 4 weeks of treatment at 1000 ppm (2.3-fold) was much lower, but still statistically significant. PROD activity has been reported to be catalyzed primarily by Cyp2b family enzymes in mice or rats, but with some contribution from other Cyps, including those in the Cyp3a subfamily Sun et al., 2006) . Sedaxane also produced a small induction of testosterone 6b-hydroxylase activity (a marker of Cyp3a activity; Arlotto et al., 1991) , but a treatment-related increase was observed only at 7000 ppm after 13 weeks (1.5-fold). This pattern of effects is consistent with the nuclear receptor reporter assays (Figure 3 ), which indicated that sedaxane was a CAR activator but not a PXR activator for mice (Elcombe et al., 2014; Lake, 2009 ). Sedaxane did not produce any increases in activity for palmitoyl-CoA oxidation or lauric acid 12-hydroxylase (an indicator of microsomal Cyp4a induction), two enzymes that are known markers of PPARa activation (Klaunig et al., 2003; Lake, 2009 ). Sedaxane did not produce any increases in EROD activity, which is a marker for Cyp1a and Cyp1b activities that are induced by AhR activation.
In rat liver samples from a 28-day study (Supplementary  Table S5 ), biochemistry measurements again suggested that induction of Cyp2b isoforms was the major change in the liver, based on the large increases in PROD activity and testosterone 16b-hydroxylase activity. This latter activity showed a statistically significant increase at 2000 and 5000 ppm in the diet (22-to 23-fold of controls), but not at 500 ppm, and it has been shown to be reflective of Cyp2b induction (Arlotto et al., 1991) . Similar to mice, a small increase in testosterone 6b-hydroxylase activity (up to 2.3-fold) was observed, a marker of Cyp3a induction, and no induction of EROD activity occurred. Concordant with the much greater Cyp2b induction at 2000 and 5000 ppm in rats, relative liver weights and centrilobular hypertrophy were increased in rats at these dose levels, but not at 500 ppm.
Altered Gene Expression in Sedaxane-Treated Mice: RT-PCR
Since all of the biochemical results, CAR and PXR reporter assay data, and liver histopathology changes from multiple studies in rats and in mice indicated that sedaxane produced a common set of effects in both species, gene expression data were obtained only in the 21-day mouse MOA study samples. The effects of dietary sedaxane treatment on the expression of selected genes in the livers of mice were evaluated by RT-PCR. Five genes were selected for analysis by RT-PCR, based on their response in a previous study (Tojima et al., 2012) in C57BL/ 6 mice given a single intraperitoneal 3 mg/kg dose of TCPOBOP at 12 h prior to necropsy (details provided in Supplementary  Table S1 ): Cyp2b10, Cyp2c65, Gadd45b, Cdc20, and Fos. In the 21-day mouse MOA study, responses for these genes were examined for mice treated with TCPOBOP as a positive control and for mice treated with sedaxane for up to 21 days (Supplementary Figure S3; data not shown for Fos).
In the mouse MOA study, treatment with either one or two 3 mg/kg doses of TCPOBOP resulted in a significant upregulation of Cyp2b10, Cyp2c65, Gadd45b, and Cdc20 mRNA levels. These responses are similar to those reported by Tojima et al. (2012) after one 3 mg/kg dose of TCOPOBOP, although the increase in Cdc20 in the current study was only observed after two doses of TCPOBOP. In contrast, no effects of TCPOBOP treatment on Fos expression were observed (data not shown), whereas Tojima et al. (2012) reported a down-regulation of this gene. Slight differences in the ability of TCPOBOP to decrease hepatic Fos mRNA levels or the timing of the increase in Cdc20 mRNA levels between these two studies could represent strain differences in the responsiveness to CAR activation for specific genes. Overall, the results of the investigations with TCPOBOP demonstrate the responsiveness of the batch of male CD-1 mice used in this study to a known CAR activator.
The treatment of male CD-1 mice with 1250, 7000, or 14 000 ppm sedaxane in their diets for 1, 3, 7, and 21 days (Days 2, 4, 8, and 22) resulted in a significant dose-dependent up-regulation of Cyp2b10 mRNA levels at all dose levels and timepoints. With the exception of the effect of treatment with 1250 ppm sedaxane at Day 22, a significant dose-dependent upregulation of Cyp2c65 mRNA levels was also observed at all dose levels and time-points. The treatment of male mice with 14 000 ppm sedaxane significantly up-regulated hepatic Gadd45b mRNA levels at Days 2, 4, and 8, and Gadd45b mRNA levels were also significantly up-regulated after treatment with 7000 ppm sedaxane at Day 2. The up-regulation of Gadd45b mRNA levels by sedaxane treatment was transient, with no significant differences in the fold-change at Day 22 of treatment. Sedaxane had no treatment-related effects on Cdc20 or Fos mRNA expression levels at any of the dose levels or time points that were examined.
Altered Gene Expression in Sedaxane-Treated Mice: Microarrays As a further exploration of the mRNA expression patterns produced by sedaxane in male CD 1 mice, Agilent Whole Mouse Genome Oligo Microarray slides were run and analyzed for liver samples from Days 2, 4, and 22 of treatment. A set of differentially expressed genes (DEGs) was obtained by comparisons of treated and control microarray results, and the patterns of DEGs were evaluated with Genespring and Ingenuity Pathways Analysis TM (IPA TM ). The total numbers of DEGs at each dose level showed a clear dose response (Supplementary Table S9) , with very minimal differences from control at the low dose level of 1250 ppm. The full DEG lists from these experiments are available in Supplementary Table S11, and comparison of the top 12-13 IPA pathways versus the top 10 IPA pathways previously identified as being most significant for known mouse CAR activating compounds (Oshida et al., 2015a ) is provided in Supplementary  Figure S4 . For the 14 000 ppm sedaxane-treated mice (Day 2), 10 of the 12 top pathways were the same as the top 10 pathways identified for known CAR activators. For 7000 ppm sedaxanetreated mice (Day 22), 9 of the 12 top pathways were the same as the top 10 pathways identified for known CAR activators. Therefore, while some of these IPA pathways have names that may not (at first glance) sound directly relevant to CAR activating compounds (eg, Melatonin degradation I and Nicotine degradation III), they reflect changes in a set of mRNAs that are consistent with changes produced by known CAR activators.
The microarray data for sedaxane-treated mice also was compared with the 83-gene CAR biomarker signature that was developed by Oshida et al. (2015a) . These authors treated wild-type and CAR-null mice with 3 model CAR activators (phenobarbital, TCPOBOP, and CITCO) for 7 days, and determined the 83-gene CAR biomarker signature based on CAR-responsive genes that also were not altered in the same direction with AhR, PPARa, Nrf2, or STAT5b activators. Comparisons to the CAR biomarker signature can be conducted with the tool NextBio.com; this analysis uses a Running Fisher's algorithm that considers both the number of matching gene expression changes and the direction of those changes in calculating a p-value. Results are expressed as -log(p-value), and the authors of Oshida et al. (2015a) determined that a -log(p-value) >4 (ie, p-value of <.0001) was an appropriate criteria for identifying true positive matches with the CAR signature, after testing 60 additional test materials. When a test compound shows a negative correlation to the biomarker signature (ie, affects the same genes in the opposite direction), the -log(p-value) is assigned a negative value in NextBio.com.
Results of this analysis for the sedaxane mouse data within the tool NextBio.com are shown in Figure 4 . For both the 7000 ppm and the 14 000 ppm sedaxane-treated mice, microarrays on Days 2 and 4 showed a statistical match with the CAR biomarker signature, with -log (p-values) of 5-8. Although the values on Day 22 were somewhat lower (2-4), the pattern across time suggests a match here as well, in particular, when considering that the CAR signature was based on 7-day treatments (Oshida et al., 2015a) . Also in Figure 4 , the sedaxane-treated microarrays did not match biomarker signatures that have been similarly developed for AhR, PPARa, and STAT5b (Oshida et al., 2015b (Oshida et al., , c, 2016 . Sedaxane showed a negative correlation with the STAT5b biomarker signature, and prior work by these authors has shown evidence of antagonism of STAT5b by known CAR activators (Oshida et al., 2015a (Oshida et al., , 2016 . Consistent with these observations, "upstream regulator analysis" within IPA showed that the 14 000 ppm sedaxane-treated group had inhibited STAT5b (p ¼ .0086) and activated genes related to CAR (p ¼ 5 Â 10 Table  S10 ):
• Large changes in characteristic genes involved in the CAR pathway were observed at 7000 ppm and 14 000 ppm, including Cyp2b10 and Cyp3a11. In contrast, only a minimal response was observed in the 1250 ppm group; and • Changes related to a potential proliferative effect in the liver included up-regulation of Gadd45b at 14 000 ppm and downregulation of Gadd45c at 7000 ppm, both of which reflect a proproliferative, anti-apoptotic signal (Liebermann et al., 2011; Ozawa et al., 2011) .
These results in the microarrays showed some quantitative differences from the results of RT-PCR analysis (Supplementary Figure S3) , such as absence of any increase in Cyp2b10 for the 1250 ppm group on Days 2 through 4, but these differences are inherent to the differing analysis methods and dependent upon the DEG filtering criteria for the microarrays. The trend in these genes by dose and time was consistent across both platforms, with much greater changes occurring at 14 000 ppm, more subtle changes observable at 7000 ppm, and minimal changes visible at 1250 ppm.
Hepatocellular Proliferation in Rats and Mice
In the 28-day MOA study in male Wistar rats, all animals received a subcutaneous injection of BrdU in sterile 0.9% sodium chloride solution approximately 2 h before termination. The formalin-fixed paraffin-embedded liver samples of all rats (along with a piece of duodenum as a positive control tissue) were processed by immunohistochemistry to detect and quantify the labeling index (%BrdU positive hepatocytes) as a measurement of S-phase or cell proliferation. Results of this BrdU labeling index determination are shown in Figure 5 . A statistically significant transient increase in hepatocellular proliferation, as indicated by an elevated hepatic BrdU labeling index, was maximal on Day 2 of treatment with sedaxane at both 1200 and 3600 ppm. Proliferation, as measured by the labeling index, was less evident on Day 4 of treatment, with only the 1200 ppm sedaxane treatment achieving a statistically significant increase, and by Day 29 of treatment, the labeling index in all the sedaxane treatment groups returned to baseline levels. After a recovery period of 60 days (Day 89), the 3600 ppm sedaxanetreated animals showed no difference from control values for BrdU labeling index. Labeling indices of the positive control (sodium phenobarbital) increased in a manner consistent with the known properties of this CAR activator, with a transient profile that was maximal at Days 2 through 4. The response to sodium phenobarbital diminished with time, but was slightly elevated through Day 29.
In the 21-day MOA study in male mice, cell proliferation was evaluated by the zonal distribution of Ki67 in the liver, as illustrated in Supplementary Figure S1 . Zone 1 corresponded to the periportal region (including the portal triad), zone 2 was the midzonal region, and zone 3 corresponded to the centrilobular region (including the hepatic vein). Ki67 is a nuclear protein that is expressed during all phases of the proliferating cell cycle (G1, S, and G2), but not during the quiescent G0 phase (Gerdes et al., 1984) . Zonal counts of hepatic labeling index by various methods have demonstrated that for some specific xenobiotics, a cytotoxic or a cell proliferation response may be detected more readily within an individual zone of the liver than by counting all zones together (Bahnemann and Mellert, 1997; Wood et al., 2015) . Results of the Ki67 analysis of male mouse livers across zones 1, 2, and 3 combined are shown in Figure 6 ; results for individual zones of the liver are presented in Supplementary  Figure S5 . In the Ki67 labeling results, a treatment-related effect was observed at the Day 8 sacrifice, as indicated by statistically significant increases (p < .05) relative to controls in mean labeling index values for Zones 1, 2, and 3 combined in the 7000 ppm and 14 000 ppm dose groups. The overall ANOVA analysis at Day 8 was also significant at p ¼ .0186. The 1250 ppm dose group was not significantly different from the control group at this time interval. At Day 22, a statistically significant decrease in Ki67 labeling index for the 1250 ppm group, in the absence of any effects at higher dose levels or other time intervals, is not considered toxicologically meaningful. The Ki67 labeling index in zones 1, 2 and 3 separately showed similar patterns to one another, and to the combined labeling index results in Figure 6 ; therefore, the separated data is included as supplemental information (Supplementary Figure S5) .
In addition to the Ki67 analysis of the liver labeling index for the sedaxane-treated mouse livers, an initial evaluation of BrdU labeling of livers was conducted. In the BrdU labeling index results (Supplementary Figure S6) , a trend toward numerically higher labeling index values at 7000 and 14 000 ppm was observed at the Day 8 time interval, but this did not achieve statistical significance. For the TCPOBOP positive control groups, a large increase in BrdU labeling index was observed on Day 4, but not on Day 2. Because the expected response to the positive control was observed in the BrdU analysis, the livers of TCPOBOP-treated mice were not evaluated for Ki67 labeling.
In summation, the combined data from Ki67 and BrdU immunohistochemistry of the mouse livers showed that a slight, treatment-related increase in cell proliferation was observed on Day 8 following treatment with 7000 and 14 000 ppm sedaxane. This proliferative response was transient, with no effect on the Ki67 labeling index observed on Day 22.
Toxicokinetics: Concentrations of Sedaxane in Rat Plasma and Mouse Blood
Comparative toxicokinetic profiles of sedaxane's two isomers in the plasma/blood of rats and mice are shown in Table 1 . The Cmax values for both species were determined based on samples taken in the morning after overnight feeding, and concentrations were measured after a single day of dosing (Day 1) or after 2 weeks of dosing at steady-state (Day 14). The blood concentrations of the trans-isomer and the cis-isomer of sedaxane in male mice were less than the limit of quantitation (LOQ < 10 ng/ml) in the majority of the mice, such that a reliable mean value could not be determined. This was the opposite of (Oshida et al., 2015a (Oshida et al., , b, c, 2016 . The 7000 ppm and 14 000 ppm sedaxane DEG lists showed a significant match (Àlog(p-value) >4) only for the CAR signature. Negative values for -log(p-value) compared with the STAT5b signature indicate changes in the opposite direction for marker genes; prior work has indicated that most CAR activators show evidence of an antagonism of STAT5b (Oshida et al., 2015a (Oshida et al., , 2016 ). the pattern found in male rats, where quantifiable Cmax concentrations that were roughly proportionate to the administered dose were consistently observed. The rat data showed that generally lower concentrations were observed on Day 14 than on Day 1, likely indicating induction of metabolizing enzymes during the first 2 weeks of sedaxane administration. In a rat 14 C-sedaxane metabolism study (data not shown), the major circulating moieties in blood at a dose of 80 mg/kg were the parent sedaxane (trans-and cis-isomers) and a demethylated metabolite (trans-and cis-isomers). The HPLC analysis of mouse blood in the 14-day study detected only trace amounts of the desmethyl sedaxane isomers in a small proportion of the mice (data not shown), ie, similar to the low levels of parent sedaxane isomers in mice. These data suggest that sedaxane is rapidly metabolized to downstream metabolites in mice and thus cleared from the blood, at a greater rate than found in the rat. This quantitative difference translates into less generalized toxicity (eg, body weight decreases) and lesser effects on the liver (eg, liver weight and hypertrophy increases) in mice than observed in rats at equivalent dose levels.
Primary Rat and Human Hepatocyte Cultures
Primary cultures of isolated hepatocytes from male Wistar rats and from cryopreserved male human hepatocytes were incubated with sedaxane at concentrations from 1 to 100 mM, and then endpoints of cytotoxicity (by ATP content), DNA labeling index (by BrdU labeling), and BROD activity (as a marker of Cyp2b/Cyp3a enzyme induction) were assessed (Supplementary Figures S7 and S8) . Under similar conditions, NaPB was tested at 10, 100, and 1000 mM to show the effects of a known CAR activator, and EGF was tested to demonstrate the BrdU labeling index for a known mitogen. In rat hepatocytes (Supplementary Figure S7) , 100 mM sedaxane reduced ATP levels to 78% of controls, an effect that was considered evidence of some cytotoxicity. Treatment with 30 lM sedaxane caused a statistically significant increase in replicative DNA synthesis as determined by the BrdU labeling index. The statistically significant decreases in replicative DNA synthesis observed at higher concentrations of sedaxane (65 and 100 lM) were considered to be a result of cytotoxicity. Treatment with NaPB or EGF resulted in statistically significant increases in replicative DNA synthesis, as expected. Treatment with sedaxane caused concentration-dependent increases in BROD activity, with statistically significant increases observed at concentrations !30 lM. NaPB produced a similar increase in BROD activity.
In human hepatocytes (Supplementary Figure S8) , sedaxane at 30, 65, and 100 mM resulted in a gradual increase in cytotoxicity, with ATP levels of 70%, 44%, and 25% of control values. As a result, replicative DNA synthesis could not be evaluated at 65 and 100 mM, and the value at 30 mM sedaxane was reduced to 51% of the control group value, due to the accompanying cytotoxicity. Microscopic examination of 30 lM sedaxane cultures revealed fewer hepatocytes present (approx. 50% of the controls), and lower cell confluence compared with the control cultures. Treatment with non-cytotoxic concentrations of 1-10 lM showed that sedaxane had no effect on the hepatocellular BrdU labeling index. Treatment with NaPB also had no effect on replicative DNA synthesis at any test concentration. In contrast, EGF resulted in a statistically significant increase in replicative DNA synthesis, as expected. Treatment with 1, 3, and 10 lM sedaxane caused concentration-dependent increases in BROD activity, which were statistically significant, whereas concentrations of !30 mM sedaxane showed a gradual decrease in BROD activity, due to the accompanying cytotoxicity. NaPB produced a concentration-dependent increase in BROD activity in the human hepatocyte cultures.
DISCUSSION
Weight of Evidence Evaluation of the Rodent Liver MOA According to the IPCS Framework (Boobis et al., 2006; Meek et al., 2014) , the sedaxane data can be evaluated for: (1) the strength, consistency, and specificity of association of the key events to the tumor response; (2) dose-concordance of key events; and (3) temporal concordance (ie, do the key events occur in a logical sequence). To illustrate these concepts for the database in rats and in mice, dose-concordance of the associative and causal key events are presented in Tables 2 and 3 , respectively. All of the data indicate that the same MOA is operative in both male rats and male mice, and therefore the data across both species can be viewed as supportive for the overall rodent MOA.
In rats, there is good dose concordance of the proposed key events with tumor outcome (Table 2) . With increasing doses, an increasing number of the key events are observed. Critically, it is only at the 3600 ppm dose level that EPA considers to be tumorigenic that all of the causal and associative key events are observed. Effects at non-tumorigenic dose levels in the range of 500-1200 ppm included short-term increases in markers of liver Cyp2b induction (eg, PROD activity), but at the lower dose of Values are mean Cmax from 28-day rat study and from a range finding 14-day mouse dietary study. In the rat study, samples were taken from 8 h after the administration of test diets and at 4-h intervals thereafter (approximately 17:00, 21:00, 01:00, 05:00, 09:00, and 13:00 h) on Days 1/2 and 14/15 of the study. Blood was centrifuged and the plasma was taken for analysis. In the mouse study, samples were taken by cardiac puncture under CO2 anesthesia into EDTA tubes at the time of sacrifice. Whole blood samples were diluted with an equal volume of water and frozen prior to analysis. Rat plasma and mouse blood samples were analyzed by HPLC for determination of the trans isomer (SYN508210) and the cis isomer (SYN508211). Tmax in rats was (in general) between 12 and 20 h into the sampling regime, which equated to the morning hours (5:00-13:00 h).
Thus, the sampling at a single sacrifice time for mice (morning) is considered a reasonable approximation of a Cmax measurement. 500 ppm, this did not translate into increased liver weight or liver hypertrophy after 28 days of treatment. The associative key events of increases in liver hepatocellular hypertrophy and liver weight were observed in a dose-responsive manner consistent with the proposed MOA. No effects on these parameters were observed at the low dose of 300 ppm from a 90-day subchronic rat study or at the low dose of 200 ppm from the 2-year rat study. In mice, dose concordance for all of the same key events was evaluated, including toxicogenomics measurements (Table 3) . The dose levels of 7000 and 14 000 ppm are considered tumorigenic, because the EPA concluded that an increased liver tumor incidence occurred at 7000 ppm in the 80-week study. At dose levels of 1000-1250 ppm evaluated in a 28-day subchronic study and the 21-day mouse MOA study, limited effects of small increases in PROD activity were observed, but no observable increases in liver weight or liver hypertrophy occurred. Further, the key event of transiently increased cell proliferation (by Ki67 staining) was only observed at the tumorigenic dose levels of 7000 and 14 000 ppm, but not at the non-tumorigenic 1250 ppm dose. Toxicogenomic evaluations (by RT-PCR and by microarrays) in mice mirrored these apical endpoints: only a few Cyp mRNAs were slightly increased at 1250 ppm, whereas much greater changes in a wider range of mRNAs, including markers of an increased pro-proliferative and anti-apoptotic environment, were observed at 7000 ppm and 14 000 ppm. Overall, the pattern of effects in the mouse liver was relatively weak in magnitude, as compared with the rat liver effects, but the dose levels where the earlier key events were uniformly observed matched with the tumorigenic dose level of !7000 ppm.
As shown in Table 1 , the concentration of sedaxane isomers in the blood was at very low levels in male mice (at or below the LOQ) after 14 days of dosing, whereas in male rats, consistently higher concentrations that were roughly proportional to dose were observed. These data suggest that sedaxane is rapidly metabolized to downstream metabolites in male mice, and thus cleared from the blood, at a greater rate than in male rats, and this quantitative difference translates into less generalized toxicity (eg, body weight decreases) and lesser effects on the liver (eg, liver weight and hypertrophy increases) in mice than in rats. Thus, the toxicokinetic data as a useful additional parameter in short-term mechanistic studies provides a likely explanation for the apparent difference in sensitivity to sedaxane in mice versus rats.
In terms of temporal concordance, the observed effects on parameters associated with the key events occur in a logical, time-dependent manner consistent with the proposed MOA in both rats and mice. Early key events, including CAR activation and changes in gene expression, as well as the associative events of hepatocellular hypertrophy and increased liver weights, occur after 1 to 7 days and tend to continue throughout treatment for rats, whereas in mice, hepatocellular hypertrophy at 7000 ppm was observed up through 21 days of treatment, but was not observed after 28 days through 18 months. Cell proliferation was an early key event in both species, with slight species differences in the time of peak effect, and this event was transient (ie, no increases after !14 days). Later key events include an eventual increase in clonal expansion of transformed cells to generate increased altered foci (>1 year, in rats), and eventually an increase in tumor incidence. The temporal relationships in rats and mice are consistent with the proposed MOA and the known biology of CAR activators (Deguchi et al., 2009; Elcombe et al., 2014; Yamada et al., 2009) . In addition, they point to a gradually diminished response in non-neoplastic changes in the livers of mice beyond 21 days, which is consistent with lower sedaxane blood concentrations and general toxicity in mice than in rats at similar dose levels.
The data supporting the MOA for liver tumors in mice and rats is strong and consistent, with a high degree of reproducibility, both between studies and between species. The only minor inconsistency in the database is the lack of an increase in eosinophilic foci in the 80-week mouse study. This late key event was clearly observed at the tumorigenic 3600 ppm dose in male rats. However, it is plausible that an increase in altered foci in the mouse liver may have preceded the development of tumors, but it could not be observed because no interim sacrifice is made in an EPA/OECD guideline mouse carcinogenicity study. In addition, this minor difference between the species is consistent with the overall pattern of much milder non-neoplastic effects on the liver occurring in mice than in rats, likely due to differences in toxicokinetics.
The induction of liver tumors in male mice subsequent to the activation of CAR is a comprehensively studied and characterized MOA for a number of compounds, including the archetypal CAR activator phenobarbital (Elcombe et al., 2014; Meek et al., 2003; Whysner et al., 1996) and the potent mouse CAR activator TCPOBOP (Huang et al., 2005) . In addition, the stated MOA and the clear dependence on CAR activation as a causal key event is consistent with the data for other SDHI fungicides that produce rodent liver tumors via this MOA, including fluopyram (ECHA, 2012; U.S. Environmental Protection Agency, 2014), penflufen (U.S. Environmental Protection Agency, 2011b), and fluxapyroxad (U.S. Environmental Protection Agency, 2011a) . The data for sedaxane in male rats and male mice are consistent with these prior results, and thus there is a high biological plausibility to the proposed MOA via CAR activation.
Alternative MOAs
In addition to CAR/PXR activation, a number of alternative MOAs for induction of liver tumors in rodents and/or humans have been demonstrated (Cohen, 2010) . These alternative MOAs, in brief, can be excluded as part of the weight of evidence evaluation for sedaxane, based on the evidence summarized below.
• Genotoxicity. Sedaxane has been tested in a wide variety of in vitro and in vivo assays for genotoxicity, and there is no evidence that sedaxane is genotoxic (U.S. Environmental Protection Agency, 2013 ).
• Peroxisome Proliferation and AhR Activation. Sedaxane showed no evidence of induction of enzymes or mRNA markers for these alternative nuclear receptor-mediated MOAs (Figure 4 , Supplementary Figure S2 and Table S5 ).
• Estrogenic Stimulation. In the full toxicological database for sedaxane, there is no evidence for estrogenic stimulation (U.S.
Environmental Protection Agency, 2013). In addition, sedaxane showed no estrogenic activity in a rat uterotrophic assay (data not shown).
• Cytotoxicity, Infection, Iron/Copper Overload. Regarding these somewhat overlapping mechanisms, sedaxane showed no increases in liver necrosis, inflammation, deposition of metals, or other markers of cytotoxicity, such as plasma ALT, AST, or ALP levels (U.S. Environmental Protection Agency, 2013) . In addition, the cell proliferation in rats and mice was marked by an early burst (1-7 days), but did not show a sustained regenerative proliferation more typical of cytotoxic agents.
Assessment of the Postulated MOA in Rats and Mice
The concordance analyses demonstrate that the proposed key events resulting in the induction of liver tumors in male rats and male mice are reproducible across a number of studies, and these exhibit strong dose-and temporal-concordance with the tumor endpoint. This is a well-described MOA for the induction of liver effects, including liver tumors in rats and mice, and the parameters essential for describing this MOA have been demonstrated experimentally for sedaxane. Therefore, there is a high level of confidence that the hypothesized MOA (Figure 1 ) was responsible for the higher incidences of liver tumors in male rats following dietary exposure to 3600 ppm sedaxane, and in male mice following exposure to 7000 ppm sedaxane.
Human Relevance Assessment
Based on the analysis in the prior section, the weight of evidence is sufficient to establish the MOA for sedaxane-mediated liver tumors in rats and mice. According to the IPCS Framework, the next step is to determine if the MOA is relevant to humans, based on (1) qualitative differences between the species, or (2) quantitative differences in kinetic or dynamic factors. Based on an evaluation of the data for sedaxane and the wider literature, human relevance of the MOA can be reasonably excluded on the basis of fundamental, qualitative differences in key events between experimental animals and humans. In brief, the evidence that leads to this conclusion is summarized below.
• Reporter assays for CAR and PXR activation, as well as comparative induction of Cyp2b and Cyp3a mRNA and enzyme activity measurements, have established that sedaxane primarily activates the CAR nuclear receptor.
• A number of studies have shown that CAR can be activated by compounds such as phenobarbital in the mouse, rat, Syrian hamster, guinea pig, and human, resulting in altered gene expression, hypertrophy, and Cyp2b enzyme induction (Diwan et al., 1986; Elcombe et al., 2014; Huang et al., 2005; Olsen et al., 1989; Weaver et al., 1994; Yamamoto et al., 2004) . In contrast, while phenobarbital enhances cell proliferation and decreases apoptosis in the mouse and rat, other species appear to be refractory to the proliferative and anti-apoptotic responses. In keeping with the lack of effect of phenobarbital on cell proliferation in the Syrian hamster (Parzefall et al., 1991) , chronic phenobarbital treatment does not produce liver tumors in this species when dosed at 500 ppm in drinking water in a long-term initiation-promotion assay (Diwan et al., 1986) .
• A number of epidemiological studies have demonstrated that, in human subjects receiving phenobarbital for many years at doses that produce plasma concentrations similar to those that are carcinogenic in rodents, there is no evidence of increased liver tumor risk (Friedman et al., 2009; IARC, 2001; Olsen et al., 1989 Olsen et al., , 1995 Whysner et al., 1996) .
• Based on a full literature review, proceedings from a public workshop in 2010 that investigated the MOA for rodent liver tumors via the CAR nuclear receptor, with phenobarbital as a test case, concluded that this CAR-mediated MOA in rodents was not relevant to humans, based on fundamental qualitative differences between the species (Elcombe et al., 2014) .
• Consistent with these previously established differences between the species, experiments with sedaxane in rat or human hepatocytes have demonstrated that the human hepatocytes do not respond to sedaxane treatment with an increase in replicative DNA synthesis, whereas rat hepatocytes do respond.
Thus, the answer to the IPCS Framework question "Can human relevance of the MOA be reasonably excluded on the basis of fundamental, qualitative differences in key events between experimental animals and humans?" is clearly "Yes" for sedaxane.
Utility of Novel Methods to Characterize Key Events in the MOA
The MOA for sedaxane in rats and mice has used traditional approaches to illustrate some key events in the proposed MOA, including later, specialized in vivo studies in male rats (a 28-day study with 6 different treatment durations) and in male mice (a 21-day study with 4 different treatment durations). However, some of the approaches utilized with sedaxane, such as Ki67 immunohistochemistry to measure cell proliferation within 3 different zones in the livers of mice, measurement of enzyme activities (PROD, BROD, EROD, and others), and toxicogenomic experiments to measure gene expression changes, are amenable to use of existing samples from required subchronic studies. Careful planning in terms of dose levels, sacrifice intervals, and/ or retention of frozen as well as fixed tissues samples (eg, liver and blood) can make these tools useful to minimize or to hopefully eliminate the need for large-scale, animal-intensive additional MOA studies after the chronic bioassays in rodents are completed. Other in vitro methods were also utilized, and these methods may help to gradually realize the vision of "Toxicity Testing for the 21st Century" (National Research Council, 2007) , namely, to move away from multiple, large-scale in vivo studies. A brief discussion of these methods and what they demonstrated about the MOA for sedaxane liver tumors is of interest for future study designs.
CAR reporter assays developed at Penn State University and validated with model CAR activators (Omiecinski et al., 2011) were employed to test the ability of sedaxane to activate CAR from mouse, rat, and human. A similar commercially available set of reporter assays was also used to examine PXR activation from these 3 species. As shown in Figure 3 and discussed earlier in Results, the CAR reporter assays showed that sedaxane was a clear and potent activator of mouse and rat CAR, with foldchange values of 19-fold and 6.3-fold, respectively. Sedaxane showed a lesser ability to activate rat PXR (4-fold), and it did not activate mouse PXR. For human nuclear receptors, sedaxane had similar levels of activation of both CAR (4-fold) and PXR (3.9-fold). Model activators of each species' CAR or PXR responded reproducibly with large fold-changes, thus demonstrating the sensitivity and robustness of the assays. Although the CAR reporter assay is primarily to detect direct CAR activators, preliminary work has shown that NaPB as an indirect CAR activator does produce a small but statistically significant activation of the luciferase reporter construct (up to 6-fold) at higher concentrations (1 mM) (Omiecinski, personal communication) . These responses in CAR and PXR reporter assays show promise for being able to detect, in a semiquantitative manner, the likely nuclear receptor activations that a molecule may elicit, and also the species differences in those responses.
Using frozen liver samples from the CD-1 mouse MOA study, whole mouse microarray data and comparisons of the differentially expressed genes (DEGs) to published mRNA signatures for activators of nuclear receptors (CAR, AhR, PPARa, and STAT5b) clearly established that sedaxane doses of 7000 and 14 000 ppm matched the gene signature for CAR (Figure 4) (Oshida et al., 2015a (Oshida et al., , b, c, 2016 . These types of comparisons have the advantage of simultaneously comparing the whole DEG list to a large number of genes (83 for the CAR signature), rather than a pre-selected small subset, and these comparisons with NEXTBIO.com also include the direction of gene changes in determining the statistical significance compared with the CAR signature. With further testing across more rodent liver tumorigens, this signature comparison tool should gradually gain wider acceptance as a method to augment, or possibly to replace, the need for extensive in vivo testing for these wellcharacterized MOAs, such as CAR, AhR, and PPARa activation.
Microarrays from the mouse study, in combination with RT-PCR of selected genes, were also useful in following both the time course and direction of changes in genes that are a part of how CAR activation mediates important changes in the rodent hepatocytes. For example, Gadd45b expression was increased both at 7000 ppm (Day 2) and at 14 000 ppm (Days 2, 4, and 8) in RT-PCR assessment (Supplementary Figure S3) , and a similar pattern of change was seen (with minor magnitude or timing differences) in the microarray results (Supplementary Table  S10 ). Augmenting this set of results, Gadd45c expression was significantly lower than found in controls on Day 22 for the 7000 ppm mice, and the availability of whole mouse microarray data enabled this difference to be observed. Gadd45b is a CARdependent co-activator that helps to signal an increase in cell proliferation and suppression of apoptosis; Gadd45c is involved in multiple functions, including cell cycle regulation, and in the liver its activation promotes cell death or growth arrest (Liebermann et al., 2011) . Thus, down-regulation of Gadd45c and up-regulation of Gadd45b would be consistent with a proproliferative, anti-apoptosis effect for sedaxane. Treatment of rats with the CAR activator phenobarbital has been shown to similarly upregulate the expression of Gadd45b and downregulate expression of Gadd45c in the liver (Ozawa et al., 2011) .
Ki67 is a nuclear protein that is expressed during all phases of the proliferating cell cycle (G1, S, and G2), but not during the quiescent G0 phase (Gerdes et al., 1984) . Zonal counts of the hepatocyte labelling index by various methods (eg, BrdU and Ki67) have demonstrated that for some specific xenobiotics, a cytotoxic or a cell proliferation response may be more readily detected within an individual zone of the liver than by counting all zones together (Bahnemann and Mellert, 1997; Wood et al., 2015) . BrdU is incorporated into newly synthesized DNA only during the S-phase of the cell cycle, and exposure of the liver to BrdU for some duration (eg, 2 h before sacrifice in the sedaxane MOA studies) is required in order to detect its incorporation into DNA. Published work comparing the utility of Ki67 to other markers of cell proliferation, such as BrdU, have shown that Ki67 can give similar or greater sensitivity than BrdU for detecting proliferation in a particular tissue (Kee et al., 2002; Muskhelishvili et al., 2003; Wood et al., 2015) . In the 21-day mouse MOA study, the Ki67 labeling index was statistically significantly increased by 7000 and 1400 ppm sedaxane on Day 8, but it was unaffected at the non-tumorigenic 1250 ppm dose (Figure 6 ). Zonal analysis of Ki67 showed that a similar increase was seen on Day 8 across each zone (1, 2, and 3) following sedaxane treatment (Supplementary Figure S5) , but zonal counts have shown a greater response in 1 particular zone for certain test compounds (Bahnemann and Mellert, 1997; Wood et al., 2015) . BrdU labeling for 2 h prior to sacrifice provided a sufficient duration to see markedly increased BrdU labeling index values in sedaxane-treated rats (Figure 5 ), but it was insufficient to allow a statistical difference to be detected for sedaxanetreated mice (Supplementary Figure S6) . It is likely that longer BrdU treatments (eg, via mini-pumping or administration in drinking water) could have allowed a statistical increase to be seen for mice, but Ki67 immunohistochemistry of the existing liver tissue was well-suited to detect increased cell proliferation as an effect of treatment at !7000 ppm sedaxane in mice.
The more subtle effects of sedaxane on liver effects and on general indicators of toxicity, such as body weight effects seen in mice by comparison to rats at equivalent or higher dose levels, warranted some further investigation via toxicokinetics. As shown in Table 1 , dose levels from 500 to 5000 ppm in male rats produced Cmax values of sedaxane isomers that roughly matched the achieved dose levels (48-445 mg/kg/day) after 14 days of treatment. In contrast, dose levels of 7000-14 000 ppm in mice produced Cmax values of sedaxane isomers that were at or below the LOQ of 10 ng/ml, despite dosing at achieved dose levels (970-2155 mg/kg/day) that were much higher than those given to rats. Mice were able to tolerate dose levels up to 7000 ppm for 18 months (900 mg/kg/day) with only a À10% numerical decrease in body weight gain versus controls that was not statistically significant, whereas male rats given 3600 ppm for 24 months (218 mg/kg/day) experienced a sustained, statistically significant decrease in body weight gain (À23% versus controls). It is very likely that a greater metabolism and clearance of sedaxane in mice produces the observed lower circulating levels of sedaxane isomers in the blood, thus causing comparatively lesser effects on the liver and on general toxicity compared with rats. Thus, collection of a limited number of blood samples can provide useful information to understand observed differences that are found in the course of subchronic and mechanistic studies in different rodent species.
CONCLUSIONS
The available data for sedaxane support the proposed MOA to account for the higher incidences of liver tumors in male rats (at 3600 ppm) and male mice (at 7000 ppm), as concluded previously by US EPA (U.S. Environmental Protection Agency, 2011c) and PMRA (PMRA, 2012) . The changes in the liver are attributable to activation of CAR (with a possible lesser activation of PXR in rats), which results in a series of well-documented downstream events, ultimately leading to a higher incidence of tumors versus the concurrent controls. The available data also demonstrate that this MOA is not relevant for human hazard/ risk assessment purposes, due to qualitative differences in response to CAR activation between rodents (rats and mice) and humans. In summary, the data support the conclusion that sedaxane does not pose a hepatocarcinogenic hazard to humans.
As a useful supplement, some of the methods and results employed in the MOA work for sedaxane illustrate promising directions that MOA studies may take, both now and in the future. In vitro CAR and PXR reporter assays have been developed and tested, and these were useful to demonstrate that sedaxane is a CAR activator in mice and in rats, and that PXR activation in rats may play a minor role in the observed liver responses. Further, the comparison of whole mouse microarray results to a published CAR biomarker signature (based on 83 genes) showed a clear, statistical match, as well as a lack of correlation to similar biomarker signatures for AhR, PPARa, and STAT5B. Also, in mice, Ki67 immunohistochemistry showed significant increases in this marker of cell proliferation, without the need to dose with a DNA labeling agent. The ability to conduct microarrays, Ki67 labeling, liver enzyme activity assessment (eg, PROD, BROD, and EROD), and other techniques such as toxicokinetics analysis with existing samples from subchronic toxicity studies offers a promising alternative to the traditional need to conduct later, specialized MOA studies after the results of chronic bioassays are known. With careful planning in terms of dose levels, sacrifice intervals, and types of samples taken for future use, these newer methods offer great promise in the spirit of "Toxicity Testing for the 21st Century," both to maximize the usefulness of current methods and to minimize the need for unnecessary additional animal testing.
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